Form 4: CERUS Director Ann Lucena Granted 60,000 Restricted Stock Units

CERUS Corporation's Director, Ann Lucena, was granted 60,000 Restricted Stock Units (RSUs) as part of the company's 2024 Equity Incentive Plan, aligning her interests with shareholder value.

Summary

• Ann Lucena, a Director of CERUS Corporation (CERS), acquired 60,000 shares of common stock on June 3, 2025.
• The acquisition represents a grant of Restricted Stock Units (RSUs) under the Issuer's 2024 Equity Incentive Plan.
• Each RSU provides a contingent right to receive one share of CERUS common stock.
• The RSUs will vest on the earlier of the first anniversary of the grant date or the day prior to the next annual meeting of stockholders, contingent upon Ms. Lucena's continuous service to the Issuer.
• Following this transaction, Ann Lucena beneficially owns a total of 172,284 shares of common stock directly.

Sentiment

Score: 7

Explanation: The sentiment is positive as it indicates alignment of a director's interests with shareholders through equity compensation, a standard and healthy corporate governance practice. It is not a major market-moving event but a routine positive.

Positives

• The grant of Restricted Stock Units to a director aligns management and board interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The use of an existing equity incentive plan (2024 Equity Incentive Plan) indicates a structured approach to executive and director compensation.

Future Outlook

The granted RSUs are subject to a vesting schedule, implying future issuance of common stock to Ann Lucena upon satisfaction of the vesting conditions, which include continuous service to the company.

Industry Context

The granting of Restricted Stock Units (RSUs) to directors is a common practice across various industries, particularly in biotechnology and medical device sectors like CERUS, as a form of long-term incentive compensation designed to retain talent and align interests with company performance.

Comparison to Industry Standards

• The grant of RSUs as part of director compensation is a standard practice in the biotechnology and medical technology industries, comparable to compensation structures seen in companies like Haemonetics Corporation or Terumo Corporation, which also utilize equity-based incentives for their board members.
• The vesting schedule, tied to service and annual meetings, is typical for such grants, ensuring continued commitment from the director.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with those of the shareholders, potentially leading to decisions that enhance long-term stock value.
• Employees: While specific to a director, such grants are part of a broader compensation philosophy that can influence employee incentive programs.

Next Steps

• The RSUs will vest on the earlier of the first anniversary of the grant date (June 3, 2026) or the day prior to the next annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

CERUS CORP, CERS, Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Grant, Director Compensation, Stock Ownership, Equity Incentive Plan